Medtronic's entry into robotic-assisted surgery market with Hugo system could boost revenue growth.

From Yahoo Finance: 2025-05-03 09:45:00

Medtronic has struggled with slow revenue growth in recent years, but its entrance into the robotic-assisted surgery market with the Hugo system could change that. The company has submitted an application to the FDA for approval of the Hugo system for urologic procedures, which could significantly impact its financial results. Despite competition from Intuitive Surgical, there is room for growth in the industry. Additionally, Medtronic’s diabetes care unit has shown strong sales growth, with potential for expansion. The company’s solid financial results and rock-solid dividend program make it an attractive investment opportunity.



Read more at Yahoo Finance: This Magnificent High-Yield Dividend Stock Just Became an Even Better Buy